BioPharma Reporter

FEBRUARY 22, 2024

MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a Â7 million Series A financing round, led by Mercia Ventures.

Gene 93

Gene Reagent Gene Therapy Production 93

BioPharma Reporter

JULY 5, 2021

Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.

Reagent 77

Reagent Gene Therapy Gene Manufacturing 77

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

BioPharma Reporter

JUNE 29, 2021

The New York based company said the deal will expand its in vitro diagnostic, cell and gene therapy support capabilities.

Reagent 52

Reagent In-Vitro Gene Therapy Gene 52

Roots Analysis

APRIL 5, 2023

In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.

Reagent 52

Reagent Marketing Gene Therapy Gene 52

BioTech 365

SEPTEMBER 2, 2020

Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors UPPSALA, Sweden–(BUSINESS WIRE)–Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction … Continue (..)

Protein 40

Protein Gene Therapy Reagent Gene 40

Roots Analysis

JUNE 1, 2022

Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Reagent Providers – Current Market Landscape. DNA Cloning Reagents Market. DNA Cloning Kit Providers – Current Market Landscape.

DNA 52

DNA Genetics Reagent Marketing 52

FDA Law Blog

JANUARY 4, 2023

The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023. The Agency referred to its 2011 FDA Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products during the town hall. Common CMC Issues for Phase 1 IND Study.

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

XTalks

JANUARY 21, 2025

The Onclarity HPV reagent pack extraction combo. Companion diagnostic for Pfizers hemophilia B gene therapy Beqvez (idanacogene elaparvovec-dzkt). The test is designed for identifying individuals with moderate to severe hemophilia B (congenital factor IX [FIX] deficiency) who may benefit from the gene therapy Beqvez.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Posted 17 May 2021 | By Joanne S. Eglovitch . Historical origins. .

Development 52

Development Gene Therapy Manufacturing Gene 52

Roots Analysis

FEBRUARY 21, 2022

Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. As a result, NGS library preparation kits have emerged as an innovative technology to overcome the challenges associated with conventional library preparation protocols.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

FEBRUARY 23, 2022

In the past two years, close to 3,220 patents related to NGS library preparation kits and reagents have been filed / granted, indicating the heightened pace of innovation. Next Generation Sequencing (NGS) Library Preparation Kits. Strong Intellectual Property Portfolio. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

OCTOBER 14, 2020

Bio-Techne’s Woburn facility produces Cloudz Cell Activation Kits, a magnetic-free bead-based technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. ” About Bio-Techne Corporation (NASDAQ: TECH).

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

pharmaphorum

DECEMBER 16, 2022

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Pete previously worked with Amazon, Babylon Health, and Sony. Other pharma supplier hires.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

XTalks

JANUARY 6, 2025

Cell and Gene Therapies Cell and gene therapies (C&GT) remain at the forefront of healthcare innovation, representing one of the fastest-growing therapeutic areas. As of March 18, 2024, the FDA has approved 36 gene therapies, with an additional 500 therapies in the pipeline. billion by 2031.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

Roots Analysis

JANUARY 27, 2025

Recent protein expression market trends showcase a growing emphasis on cell free protein expression systems, advanced bioinformatics, and the rise of the protein expression market for kits and reagents. Patients are increasingly seeking personalized therapies, stimulating the demand for customizable and scalable protein expression platforms.

Protein 40

Protein Reagent Marketing Gene 40